Renowned pharma giants, Bayer AG and Johnson & Johnson, have made it to the front page for the successful trial of their top-notch clot prevention drug, Xarelto. As per reports released, Xarelto exhibited the potential to reduce the risk of heart attacks in patients with atherosclerosis as well as deadly strokes by an astonishing 24% - a discovery which may essentially lead both the companies to mint billions through drug sales. In fact, predictions claim that the blood thinner’s sales could result in earnings of around USD 1.5 billion in the United States alone.
The results of the trial are likely to strengthen Bayer’s drug domain, which, according to investors, may be in a reproachful state due to lack of funds, perhaps riding on the heels of the pharmaceutical market giant’s acquisition of the Monsanto, for a valuation of USD 66 billion. Despite the successful results of the trial, Bayer may face sales obstacles in 2024 – the year that marks the expiry of Xarelto’s patent. If sources are to be believed, so far, Bayer does not possess an equally strong drug in its portfolio that is powerful and effective enough to step in for the absence of Xarelto post two back-to-back setbacks in the early stages of development.
A notable breakthrough:
In a study published in the New England Journal of Medicine and exhibited at the annual meeting of the European Society of Cardiology at Barcelona, it was depicted that a combination of aspirin and a low dosage of Xarelto is powerful to curtail the risks of heart attacks and strokes. Reportedly, the super combo is likely to cut down the risks of strokes by around 42%, heart attacks by 14%, and death by 18%.
Speaking of the irregular heartbeat market, it is to be noted that Xarelto has been deadlocked in a war of sorts, with Eliquis, conceived by Bristol-Myers Squibb and Pfizer, in addition to Pradaxa, owned by Boehringer Ingelheim. However, neither of the aforementioned pharmaceutics have so far been clinically tested in the atherosclerosis frame of reference, perhaps due to concerns regarding potentially harmful side-effects. This may however, only prove to be beneficial for Xarelto, given that it is the only privileged drug that has depicted remarkable results in patients having experienced heart attacks and strokes. It now remains to be seen whether Xarelto’s commercialization by the end of 2017 would usher Bayer and Johnson & Johnson into a profoundly remunerative landscape.
Saipriya Iyer develops content for Market Size Forecasters. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website content writing, content auditing, tech w...